Aurora, Sequana deal

Under a three-year agreement in functional genomics, SQNA will use Aurora's technologies to analyze the function of disease genes, and Aurora will develop ultra-high throughput screens for genetic targets identified at SQNA. In addition, SQNA receives exclusive access to Aurora's technologies for positionally cloned genes. Aurora's technology uses fluorescence-based screens in mammalian cells for drug discovery (see Emerging Company Profile, BioCentury March 18). ...